{"name":"Medicis Global Service Corporation","slug":"medicis-global-service-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide","genericName":"Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide","slug":"minocycline-clindamycin-tretinoin-benzoyl-peroxide","indication":"Other","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Product 55394","genericName":"Product 55394","slug":"product-55394","indication":"Moderate to severe acne","status":"phase_3"}]}],"pipeline":[{"name":"Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide","genericName":"Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide","slug":"minocycline-clindamycin-tretinoin-benzoyl-peroxide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Product 55394","genericName":"Product 55394","slug":"product-55394","phase":"phase_3","mechanism":"Product 55394 is a topical gel used to treat moderate to severe acne.","indications":["Moderate to severe acne"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOaEw1MEFKV1hnNnRZOWRqc0NoSWtrNVVxODc1Znhfc1hXNWhKbjd0aGNjYXJZSFA1WUt3SUxNQXo3QXByVUlVQjRWWGJoYllES05YemZtcXlOdlpFU0JOQVpxSVJPMEdnRGR6N0NCTkFQMklDaWpiTzBDNHB6dW1xRw?oc=5","date":"2024-07-17","type":"pipeline","source":"Fast Company","summary":"These are the companies JD Vance has invested in as a VC (and beyond) - Fast Company","headline":"These are the companies JD Vance has invested in as a VC (and beyond)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQYkhBV2psN1dFYXM4TXh1LXlWRTBjTWVoWC0wS3h6UUVYVUhHVlF3R1hzS2oxZjVXZEloaGRXdFVYdWRDN3hrVFpEcVFOVi1vNHNMbWFpZjc2WXRLaXc2QTNUMnJjX1BybWpxdGlKTzdmOXRKUHhNZUc2RzR4YUNZOWRKMFk0YWRQdlpxRW9LRkNPMmJv?oc=5","date":"2024-06-18","type":"regulatory","source":"openPR.com","summary":"Tinea Pedis Market Outlook 2032: FDA Approvals, Clinical - openPR.com","headline":"Tinea Pedis Market Outlook 2032: FDA Approvals, Clinical","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}